What is Boston Scientific's litigation payment exclusion from ebitda?

Boston Scientific (BSX) reported litigation payment exclusion from ebitda of $1.00B in Q3 2025.

How has Boston Scientific's litigation payment exclusion from ebitda changed year-over-year?

Boston Scientific's litigation payment exclusion from ebitda decreased by 0.0% year-over-year, from $1.00B to $1.00B.

Litigation payment exclusion from EBITDA

Boston Scientific Litigation payment exclusion from EBITDA remained flat by 0.0% to $1.00B in Q3 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $1.00B to $1.00B.

Analysis

StatementBalance Sheet Statement

SectionOther

First reportedQ1 2023

Last reportedQ3 2025

Metric ID: other_litigation_payment_exclusion_from_ebitda

Historical Data

9 periods

	Q1 '23	Q2 '23	Q3 '23	Q1 '24	Q2 '24	Q3 '24	Q1 '25	Q2 '25	Q3 '25
Value	$1.00B	$1.00B	$1.00B	$1.00B	$1.00B	$1.00B	$1.00B	$1.00B	$1.00B
QoQ Change	—	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%
YoY Change	—	—	—	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%	+0.0%

Range$1.00B – $1.00B

CAGR+0.0%

Avg YoY Growth+0.0%

Median YoY Growth+0.0%

Current Streak8+ quarters growth

Frequently Asked Questions

What is Boston Scientific's litigation payment exclusion from ebitda?: Boston Scientific (BSX) reported litigation payment exclusion from ebitda of $1.00B in Q3 2025.
How has Boston Scientific's litigation payment exclusion from ebitda changed year-over-year?: Boston Scientific's litigation payment exclusion from ebitda decreased by 0.0% year-over-year, from $1.00B to $1.00B.